| erectile dysfunction (ed) |
|
Erectile dysfunction (ED) has been classified as psychogenic, arteriogenic, neurogenic, endocrinologic, and cavernosal, based on the organs that are involved in penile erection.
|
| |
|
Erectile dysfunction (ED) is a common problem in the United States, with estimates that 30 million men suffer with some degree of ED.
|
| |
|
Erectile dysfunction (ED) has been the most neglected complication of diabetes.
|
| |
|
Men with diabetes are especially prone to neuronal and endothelial disease and are afflicted with erectile dysfunction (ED) at a much higher incidence and prevalence than normal men, with a consequent reduction in quality of life.
|
| |
|
Erectile dysfunction (ED) is more commonly seen in men with various components of the metabolic syndrome (a constellation of various cardiovascular and diabetes risk factors).
|
| |
|
There are numerous publications based on sophisticated community and clinical-based data, suggesting a strong and consistent association between LUTS and erectile dysfunction (ED).
|
| |
|
The introductionof the first efficacious and safe oral medication (sildenafil) resulted in the expansion of the patient base and, the change in health care delivery, with erectile dysfunction (ED) entering the primary care physician's practice.
|
| |
|
Erectile dysfunction (ED) is the most common male sexual dysfunction encountered in the clinical setting.
|
| |
|
Restoration of sexual function to HIV-positive men with erectile dysfunction (ED) is a challenging problem with many faces.
|
| |
|
Many diabetic men suffer from erectile dysfunction (ED).
|
| |
|
Erectile dysfunction (ED) is a multisystemic disorder most commonly caused by vascular insufficiency.
|
| |
|
Erectile dysfunction (ED) is often not considered in the same context as such traditional cardiovascular conditions as hypertension, dyslipidemia, diabetes, or ischemic heart disease.
|
| |
|
For the past three decades, long before oral therapy was introduced, penile revascularization has been used as a therapeutic option in patients with erectile dysfunction (ED).
|
| |
|
Penile revascularization (PR) to treat erectile dysfunction (ED) became popular in an era when there were few alternative therapies available.
|
| |
|
Erectile dysfunction (ED) affects a significant proportion of men, starting in middle age, with a substantial increase with each passing decade of life.
|
| |
|
This study tested the hypothesis that sildenafil daily for 1 year can cure vascular erectile dysfunction (ED).
|
| |
|
Most guidelines recommend only history, physical examination, and limited laboratory testing before instituting oral therapies for erectile dysfunction (ED).
|
| |
|
Erectile dysfunction (ED), defined as the consistent inability to obtain and/or maintain penile erection sufficient for satisfactory sexual relations, is associated with a variety of medical, psychological, and lifestyle risk factors.
|
| |
|
Despite the development of effective oral phosphodiesterase type 5 (PDE5) inhibitors for treatment of erectile dysfunction (ED), millions of men remain refractory to this class of drug.
|
| |
|
Initial placebo-controlled trials with sublingual apomorphine showed promising results for the drug as an option in the pharmacologic management of erectile dysfunction (ED).
|
| |